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Editorial
Incompatible: end- of- life care 
and health economics
Katharina Diernberger,1 Bethany Shinkins,2 Peter Hall,1 
Stein Kaasa,3 Marie Fallon   4
When it comes to death, the 
statistics are stark. 100% of us 
will die. The question is what 
are we all going to do about 
that? How are we going to 
create confidence in the care 
that we may need?1
During the last year of life, major 
healthcare resources are spent, not 
only in lifetime monetary terms, but 
also on professional time. Reflecting 
on this quote, it seems counterintu-
itive that health economics could 
play a major role in tackling the 
main challenges in end of life care. 
However, the escalating cost of 
healthcare, combined with an ever- 
increasing range of therapeutic and 
patient management options, has 
brought difficult budget allocation 
decisions to the fore.
WHAT IS THE VALUE OF HEALTH 
CARE?
The value of healthcare can be 
considered as what is gained rela-
tive to what is lost. In our context, 
there are three value dimensions:
1. Population: how well assets are 
distributed to different subgroups 
in society (equity in resource 
distribution).
2. Technical: how well resources are 
used for outcomes for all people in 
need in the population (improving 
quality and safety of services).
3. Personal: how well the outcome re-
lates to the values of each individual 
(understanding what matters most 
to the patient).
Contrary to popular misconception, 
value is not the same as quality of 
care or how much money is spent. 
High- quality care to the wrong 
patient or at the wrong time (or in 
the wrong place), is still low value. 
Similarly, better value is not neces-
sarily achieved by more money. 
Nevertheless, even to the right 
person at the right time, it will still 
have an inevitable cost
However, maximising value 
in healthcare resources requires 
understanding both what we seek 
to achieve and the effectiveness of 
the means to achieve it; this is the 
purpose of health economics.
People used to a universal health-
care system may struggle to see the 
value of healthcare, rather than 
perceive it as a basic right and rarely 
question where these resources 
originate.
WHAT IS HEALTH ECONOMICS?
‘Economics is a science which 
studies human behaviour as a rela-
tionship between ends and scarce 
means which have alternative use’.2 
Thus, economics is a science of 
choice. Health economics is there-
fore the science of choice within 
the healthcare context. The aim is 
to distribute a constrained health 
budget to maximise overall popula-
tion health.
A key concept of economic theory 
is ‘opportunity cost’, defined as ‘(t)
he value of forgone benefit which 
could be obtained from a resource 
in its next best alternative use’.3 
Fundamentally, money spent on 
a certain intervention/treatment/
drug cannot be spent on something 
else—even though that may also 
have had a beneficial outcome. In 
reality, healthcare systems are so 
complex that the opportunity cost 
is typically NOT identifiable, that 
is, we do not know what other 
healthcare intervention we may 
have displaced.
The economic evaluation frame-
work quantifies the pros and cons 
of specific health interventions 
and balances them against the cost 
(which might be to the system or the 
individual). With such a framework, 
we can therefore reduce ‘waste’ by 
identifying and exchanging treat-
ments that may be of minimal 
benefit for more effective ones.
HEALTH ECONOMICS AND 
PALLIATIVE CARE
The care of terminal or highly 
symptomatic disease is expen-
sive, with both a financial and 
capacity strain on individuals and 
local and national health systems 
globally. This is exacerbated by a 
demographic shift in age distribu-
tion; people live longer with more 
health needs in later life. Medical 
and technological advances expand 
treatment options, many at great 
cost. For example, new anticancer 
treatments, like immunotherapies 
and targeted anticancer therapies 
improve progression- free survival, 
sometimes overall survival but 
significantly increase costs at end of 
life. Drugs recently approved by the 
National Institute for Health and 
Care Excellence (NICE) for poor 
prognosis cancers typically cost 
about an extra £50 000 for each 
quality of life- adjusted year (QALY) 
gained—a composite measure 
of individual quality of life and 
survival.
As the healthcare budget is 
constrained, hard choices must 
be made. Real patient care has 
numerous challenges and limits on 
finance and appropriate health-
care worker time. One important 
example is community care, which 
is largely dependent on the number 
of available informal carers. Priori-
tising between this type of care and 
palliative anticancer treatments is an 
inherent tension. Health Economic 
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evaluations assist decision making 
on a larger scale, like the choice 
between additional palliative care 
beds or new drugs and more inten-
sive care.
PROBLEMS OF HEALTH 
ECONOMICS IN PALLIATIVE CARE
As health economics informs deci-
sion making, influencing the quan-
tity, quality and sustainability of 
healthcare resources, it is imper-
ative this methodology is applied 
to the highest possible standards. 
Within the UK, a standard approach 
to compare the cost- effectiveness of 
interventions has been established 
by decision makers like NICE. It 
relies on the costs to the National 
Health Service (NHS) and social 
care balanced against differences in 
QALYs.
For several reasons, this approach 
falls short when evaluating inter-
ventions at the end of life.
 ► First, a significant proportion of 
the important costs are likely to be 
incurred outside of the NHS, the 
charitable sector, the welfare state 
or the individual and their fami-
lies and/or carers. These currently 
fall outside of a NICE standard 
economic evaluation.
 ► Second, it is inaccurate to measure 
patient benefits because the 
improved function is not expected. 
The standard methods for quanti-
fying health outcomes are problem-
atic in end- of- life care as the patient 
needs/focus are different than in 
those expected to improve.
 ► Third, the QALY is the recom-
mended tool for capturing health 
outcomes across different clinical 
and disease areas. However, the 
ability of the QALY to capture 
aspects of health important to 
patients in an end- of- life context 
has been questioned given the aim 
at that juncture is neither improved 
survival nor function. The aims are 
to prevent and treat symptoms, 
preserve function, shared decision 
making and family care.
New research programmes are 
testing different strategies of better 
capturing patients’ priorities at the 
end of life like the burden of illness 
measures or palliative- specific 
quality of life measurements such as 
Investigative Choice Experiments 
of CAPablility measures.
WHY IS IT URGENT?
Worldwide, the financial cost to 
an individual with severe illness is 
significant. In the USA, the risk of 
bankruptcy increases by 250% with 
a cancer diagnosis.4 Even in the UK 
where healthcare is free at delivery, 
those with a cancer diagnosis were 
found, on a monthly average, to be 
£570 poorer.5
In the UK, most people die in 
hospital, despite it being the least 
preferred location.6 Many may 
have unnecessary clinical interven-
tions unlikely to impact quality and/
or length of life.7 Hospital care is 
expensive but comprehensive palli-
ative care at home may also be 
costly.
Tailored end- of- life care inte-
grated into public healthcare 
reduces emergency hospital and 
intensive care unit admissions and 
length of hospital stay.8 9 A more 
personalised approach therefore 
has great potential to avoid unnec-
essary resource use while simultane-
ously benefitting the patient.
In the UK, all these issues are 
being tackled by a new national 
strategy to redesign palliative care 
services. But is it a need to prior-
itise, for example, between expen-
sive new drugs with limited life 
prolongation and little evidence of 
improved symptom management or 
a basic human right to good end of 
life care? In line with national ambi-
tions for personalised care, advanced 
care planning is at the heart of this 
strategy, where patients should have 
realistic high- quality choices at the 
end of life.1 10 The effectiveness 
of sustainable integrated palliative 
care programmes11—including the 
funding of end- of- life services—is 
well documented12 and it may be 
best to prioritise such interventions 
in a public health system.
How much a society is able 
and prepared to spend on 
those who are sick and face 
approaching death may 
differ; views will vary across 
(and within) continents and 
countries and between faith 
and value systems.13
The goal therefore should be to 
reduce the financial burden of care 
of the dying on the healthcare system 
without compromising the level of 
care or a person’s quality of life. If 
the palliative care clinical commu-
nity accepts available resources are 
constrained, then extensive work is 
necessary to better understand the 
value at the end of life.
Acknowledgements The authors are 
grateful for support from Cancer 
Research UK.
Contributors All authors contributed to 
this editorial.
Funding The authors have not declared a 
specific grant for this research from any 
funding agency in the public, commercial 
or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not 
required.
Provenance and peer review Not 
commissioned; internally peer reviewed.
Open access This is an open access 
article distributed in accordance with 
the Creative Commons Attribution 4.0 
Unported (CC BY 4.0) license, which 
permits others to copy, redistribute, 
remix, transform and build upon this 
work for any purpose, provided the 
original work is properly cited, a link 
to the licence is given, and indication of 
whether changes were made. See: https:// 
creativecommons. org/ licenses/ by/ 4. 0/.
© Author(s) (or their employer(s)) 2021. 
Re- use permitted under CC BY. Published 
by BMJ.
To cite Diernberger K, Shinkins B, Hall P, et al. BMJ 
Supportive & Palliative Care Epub ahead of print: 
[please include Day Month Year]. doi:10.1136/
bmjspcare-2020-002388
Received 1 May 2020
Accepted 12 May 2020
ORCID iD
Marie Fallon http:// orcid. org/ 0000- 0001- 
9214- 0091
REFERENCES
 1 NHS. Ambitions for palliative and 
end of life care: a national framework 

































are: first published as 10.1136/bm





3Diernberger K, et al. BMJ Supportive & Palliative Care 2021;0:1–3. doi:10.1136/bmjspcare-2020-002388
Editorial
http:// endo flif ecar eamb itions. org. 
uk/ wp- content/ uploads/ 2015/ 09/ 
Ambitions- for- Palliative- and- End- of- 
Life- Care. pdf
 2 Robbins L. The nature and significance 
of economic science. In: The philosophy 
of economics: an anthology. Vol 1. 
Cambridge University Press, 1932: 
73–99.
 3 Ferraro PJ, Taylor LO. Do economists 
recognize an opportunity cost when 
they see one? A dismal performance 
from the dismal science. Contrib Eco 
Anal Pol 2005;4:10.
 4 Ramsey S, Blough D, Kirchhoff A, et al. 
Washington state cancer patients found 
to be at greater risk for bankruptcy 
than people without a cancer diagnosis. 
Health Aff 2013;32:1143–52.
 5 McMillan Cancer Support.. The financial 
impact of cancer – a growing issue, 2017. 
Available: https://www. macmillan. org. 
uk/_ images/ MAC16493% 20Money% 
20and% 20Cancer% 20policy% 20report_ 
tcm9- 314796. pdf
 6 ONS. Deaths registered in England 
and Wales, 2017. Available: https://
www. ons. gov. uk/ peop lepo pula tion andc 
ommunity/ birt hsde aths andm arriages/ 
deaths/ bulletins/ deat hsre gist rati onsu 
mmar ytables/ 2017 [Accessed 29 Nov 
2018].
 7 Hughes- Hallet T, Craft A, Davies C, 
et al. Palliative care funding review. 
funding the right care and support 
for everyone, 2011. Available: https:// 
assets. publishing. service. gov. uk/ 
government/ uploads/ system/ uploads/ 
attachment_ data/ file/ 215107/ dh_ 
133105. pdf [Accessed 27 Nov 2018].
 8 Morris ZS, Fyfe M, Momen N, et al. 
Understanding hospital admissions close 
to the end of life (ACE) study. BMC 
Health Serv Res 2013;13:89.
 9 Trtchounian A, Aberger K, Nelson J. 
292 early palliative care consultation 
associated with decreased length of stay. 
Ann Emerg Med 2017;70:S115.
 10 Kirchhoff KT, Hammes BJ, Kehl 
KA, et al. Effect of a disease- specific 
advance care planning intervention 
on end- of- life care. J Am Geriatr Soc 
2012;60:946–50.
 11 Kaasa S, Loge JH, Aapro M, et al. 
Integration of oncology and palliative 
care: a Lancet oncology Commission. 
Lancet Oncol 2018;19:e588–653.
 12 Kaasa S, Knudsen AK, Lundeby T, 
et al. Integration between oncology 
and palliative care: a plan for the next 
decade? Tumori 2017;103:1–8.
 13 Round J, ed. Care at the end of life: an 

































are: first published as 10.1136/bm
jspcare-2020-002388 on 8 M
arch 2021. D
ow
nloaded from
 
